13 citations
,
September 2022 in “International Journal of Molecular Sciences” This study identifies five compounds, including gemcitabine and methylene blue, that inhibit SADS-CoV and suggests their potential for developing antiviral drugs against future outbreaks.
8 citations
,
August 2022 in “Pharmaceutics” This study found that erythrocyte-anchored CPA-encapsulated nanoparticles improved the delivery and accumulation of Cepharanthine in the lungs, enhancing its effectiveness in treating acute lung injury by reducing inflammatory responses.
34 citations
,
June 2022 in “Viruses” This study found that the natural alkaloid cepharanthine effectively inhibited porcine epidemic diarrhea virus infection in newborn piglets.
14 citations
,
April 2022 in “Molecules” This study found that pulmonary delivery of cepharanthine significantly improved bioavailability and may provide protective effects against pulmonary fibrosis related to COVID-19 infection in a rat model.
30 citations
,
December 2021 in “Frontiers in Microbiology” In this study, researchers found that cepharanthine significantly inhibited HSV-1 replication in vitro by interfering with specific signaling pathways, arresting the cell cycle, and inducing apoptosis in infected cells, highlighting its potential as an antiviral agent.
29 citations
,
November 2021 in “FEBS Open Bio” In this study, molecular docking simulations and cell-based assays suggested that certain analogues of cepharanthine might possess anti-SARS-CoV-2 activity.
100 citations
,
November 2021 in “Cell Research” This study found that SARS-CoV-2 hijacks the host factor IGF2BP1 to stabilize its RNA and enhance translation, and identified Cepharanthine and Trifluoperazine as potential treatments against the virus.
23 citations
,
October 2021 in “AAPS PharmSciTech”
44 citations
,
February 2021 in “Scientific Reports” This study found that specific mutations in the spike protein of SARS-CoV-2 may significantly alter its structure and affect how it binds to certain inhibitors, but experimental studies are needed to confirm potential clinical implications.
45 citations
,
January 2021 in “Drug Delivery” In this study, researchers developed a biomimetic anti-inflammatory nanosystem (MM-CEP/NLCs) that significantly reduced the severity of acute lung injury in vivo by targeting and accumulating in lung inflammation sites, showcasing its potential for treating inflammation.
7 citations
,
December 2020 in “Clinical and Experimental Dermatology” This study found that cepharanthine and its structural analogues may stimulate hair growth by promoting the proliferation of human dermal papilla cells and increasing VEGF expression in vitro.
70 citations
,
July 2020 in “Pharmacological Reports” This review discusses the antiviral potential of cepharanthine against SARS-CoV-2, noting its effectiveness in preclinical models but presenting no new clinical results.
125 citations
,
May 2019 in “Phytomedicine” This review discusses the historical development, mechanisms of action, and potential new clinical applications of the drug cepharanthine, highlighting its multi-faceted pharmacological properties; it reports no new clinical results.
13 citations
,
October 2013 in “The Journal of Dermatology” This study found that topical cepharanthine increased IGF-I production in human dermal papilla cells, suggesting it may stimulate hair growth and be a promising treatment option for androgenetic alopecia.
36 citations
,
October 2002 in “The Journal of Dermatology” This study suggests that combining topical squaric acid dibutylester with other therapies may improve hair regrowth in patients with alopecia areata unresponsive to topical therapy alone.
26 citations
,
October 1997 in “Planta Medica” This study found that bisbenzylisoquinoline alkaloids from Stephania cepharantha Hayata stimulated growth in cultured murine hair cells but not in keratinocytes or fibroblasts.
23 citations
,
September 1992 in “Archives of Dermatological Research” Cepharanthine and minoxidil promote cell growth and delay hair cell maturation.